Skip to main content
NCBI home page
Molecular Medicine logoLink to Molecular Medicine
. 1996 Sep;2(5):545–555.

Induction of antigen-specific tumor immunity by genetic and cellular vaccines against MAGE: enhanced tumor protection by coexpression of granulocyte-macrophage colony-stimulating factor and B7-1.

H Büeler 1, R C Mulligan 1
PMCID: PMC2230202  PMID: 8898371

Abstract

BACKGROUND: A number of tumors express antigens that are recognized by specific cytotoxic T cells. The normal host immune responses, however, are not usually sufficient to cause tumor rejection. Using appropriate immunization strategies, tumor-specific antigens may serve as targets against which tumor-destructive immune responses can be generated. MAGE-1 and MAGE-3 are two clinically relevant antigens expressed in many human melanomas and other tumors, but not in normal tissues, except testis. Here, we have investigated whether DNA and cellular vaccines against MAGE-1 and MAGE-3 can induce antigen-specific anti-tumor immunity and cause rejection of MAGE-expressing tumors. MATERIALS AND METHODS: Mice were immunized against MAGE-1 and MAGE-3 by subcutaneous injection of genetically modified embryonic fibroblasts or intramuscular injection of purified DNA. Mice were injected with lethal doses of B16 melanoma cells expressing the corresponding MAGE antigens or the unrelated protein SIV tat, and tumor development and survival were monitored. RESULTS: Intramuscular expression of MAGE-1 and MAGE-3 by plasmid DNA injection and subcutaneous immunization with syngeneic mouse embryonic fibroblasts transduced with recombinant retroviruses to express these antigens induced specific immunity against tumors expressing MAGE-1 and MAGE-3. Both CD4+ and CD8+ T cells were required for anti-tumor immunity. Coexpression of granulocyte-macrophage colony-stimulating factor (GM-CSF) or B7-1 significantly increased anti-tumor immunity in an antigen-specific manner and resulted in a considerable proportion of mice surviving lethal tumor challenge. CONCLUSIONS: Our results suggest that genetic and cellular vaccines against MAGE and other tumor antigens may be useful for the therapy of tumors expressing specific markers, and that GM-CSF and B7-1 are potent stimulators for the induction of antigen-specific tumor immunity.

Full text

PDF
545

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allison J. P. CD28-B7 interactions in T-cell activation. Curr Opin Immunol. 1994 Jun;6(3):414–419. doi: 10.1016/0952-7915(94)90120-1. [DOI] [PubMed] [Google Scholar]
  2. Amar-Costesec A., Godelaine D., Stockert E., van der Bruggen P., Beaufay H., Chen Y. T. The tumor protein MAGE-1 is located in the cytosol of human melanoma cells. Biochem Biophys Res Commun. 1994 Oct 28;204(2):710–715. doi: 10.1006/bbrc.1994.2517. [DOI] [PubMed] [Google Scholar]
  3. Bakker A. B., Schreurs M. W., de Boer A. J., Kawakami Y., Rosenberg S. A., Adema G. J., Figdor C. G. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med. 1994 Mar 1;179(3):1005–1009. doi: 10.1084/jem.179.3.1005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Boon T., Cerottini J. C., Van den Eynde B., van der Bruggen P., Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol. 1994;12:337–365. doi: 10.1146/annurev.iy.12.040194.002005. [DOI] [PubMed] [Google Scholar]
  5. Boon T., Coulie P., Marchand M., Weynants P., Wölfel T., Brichard V. Genes coding for tumor rejection antigens: perspectives for specific immunotherapy. Important Adv Oncol. 1994:53–69. [PubMed] [Google Scholar]
  6. Boël P., Wildmann C., Sensi M. L., Brasseur R., Renauld J. C., Coulie P., Boon T., van der Bruggen P. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity. 1995 Feb;2(2):167–175. doi: 10.1016/s1074-7613(95)80053-0. [DOI] [PubMed] [Google Scholar]
  7. Brichard V., Van Pel A., Wölfel T., Wölfel C., De Plaen E., Lethé B., Coulie P., Boon T. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1993 Aug 1;178(2):489–495. doi: 10.1084/jem.178.2.489. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Castelli C., Storkus W. J., Maeurer M. J., Martin D. M., Huang E. C., Pramanik B. N., Nagabhushan T. L., Parmiani G., Lotze M. T. Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J Exp Med. 1995 Jan 1;181(1):363–368. doi: 10.1084/jem.181.1.363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Conry R. M., LoBuglio A. F., Loechel F., Moore S. E., Sumerel L. A., Barlow D. L., Curiel D. T. A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity. Gene Ther. 1995 Jan;2(1):59–65. [PubMed] [Google Scholar]
  10. Cox A. L., Skipper J., Chen Y., Henderson R. A., Darrow T. L., Shabanowitz J., Engelhard V. H., Hunt D. F., Slingluff C. L., Jr Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science. 1994 Apr 29;264(5159):716–719. doi: 10.1126/science.7513441. [DOI] [PubMed] [Google Scholar]
  11. Danos O., Mulligan R. C. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad Sci U S A. 1988 Sep;85(17):6460–6464. doi: 10.1073/pnas.85.17.6460. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. De Plaen E., Arden K., Traversari C., Gaforio J. J., Szikora J. P., De Smet C., Brasseur F., van der Bruggen P., Lethé B., Lurquin C. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics. 1994;40(5):360–369. doi: 10.1007/BF01246677. [DOI] [PubMed] [Google Scholar]
  13. Dranoff G., Jaffee E., Lazenby A., Golumbek P., Levitsky H., Brose K., Jackson V., Hamada H., Pardoll D., Mulligan R. C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3539–3543. doi: 10.1073/pnas.90.8.3539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Fung-Leung W. P., Schilham M. W., Rahemtulla A., Kündig T. M., Vollenweider M., Potter J., van Ewijk W., Mak T. W. CD8 is needed for development of cytotoxic T cells but not helper T cells. Cell. 1991 May 3;65(3):443–449. doi: 10.1016/0092-8674(91)90462-8. [DOI] [PubMed] [Google Scholar]
  15. Gaugler B., Van den Eynde B., van der Bruggen P., Romero P., Gaforio J. J., De Plaen E., Lethé B., Brasseur F., Boon T. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med. 1994 Mar 1;179(3):921–930. doi: 10.1084/jem.179.3.921. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Guéry J. C., Adorini L. Dendritic cells are the most efficient in presenting endogenous naturally processed self-epitopes to class II-restricted T cells. J Immunol. 1995 Jan 15;154(2):536–544. [PubMed] [Google Scholar]
  17. Hodge J. W., McLaughlin J. P., Abrams S. I., Shupert W. L., Schlom J., Kantor J. A. Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity. Cancer Res. 1995 Aug 15;55(16):3598–3603. [PubMed] [Google Scholar]
  18. Hoon D. S., Yuzuki D., Hayashida M., Morton D. L. Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen. J Immunol. 1995 Jan 15;154(2):730–737. [PubMed] [Google Scholar]
  19. Huang A. Y., Golumbek P., Ahmadzadeh M., Jaffee E., Pardoll D., Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science. 1994 May 13;264(5161):961–965. doi: 10.1126/science.7513904. [DOI] [PubMed] [Google Scholar]
  20. Kawakami Y., Eliyahu S., Delgado C. H., Robbins P. F., Rivoltini L., Topalian S. L., Miki T., Rosenberg S. A. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3515–3519. doi: 10.1073/pnas.91.9.3515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Kocher T., Schultz-Thater E., Gudat F., Schaefer C., Casorati G., Juretic A., Willimann T., Harder F., Heberer M., Spagnoli G. C. Identification and intracellular location of MAGE-3 gene product. Cancer Res. 1995 Jun 1;55(11):2236–2239. [PubMed] [Google Scholar]
  22. Kuchroo V. K., Das M. P., Brown J. A., Ranger A. M., Zamvil S. S., Sobel R. A., Weiner H. L., Nabavi N., Glimcher L. H. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell. 1995 Mar 10;80(5):707–718. doi: 10.1016/0092-8674(95)90349-6. [DOI] [PubMed] [Google Scholar]
  23. Kuppner M. C., Hamou M. F., Bodmer S., Fontana A., de Tribolet N. The glioblastoma-derived T-cell suppressor factor/transforming growth factor beta 2 inhibits the generation of lymphokine-activated killer (LAK) cells. Int J Cancer. 1988 Oct 15;42(4):562–567. doi: 10.1002/ijc.2910420416. [DOI] [PubMed] [Google Scholar]
  24. Levitsky H. I., Lazenby A., Hayashi R. J., Pardoll D. M. In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med. 1994 Apr 1;179(4):1215–1224. doi: 10.1084/jem.179.4.1215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Major M. E., Vitvitski L., Mink M. A., Schleef M., Whalen R. G., Trépo C., Inchauspé G. DNA-based immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid. J Virol. 1995 Sep;69(9):5798–5805. doi: 10.1128/jvi.69.9.5798-5805.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Miller A. D. Retrovirus packaging cells. Hum Gene Ther. 1990 Spring;1(1):5–14. doi: 10.1089/hum.1990.1.1-5. [DOI] [PubMed] [Google Scholar]
  27. Mizoguchi H., O'Shea J. J., Longo D. L., Loeffler C. M., McVicar D. W., Ochoa A. C. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science. 1992 Dec 11;258(5089):1795–1798. doi: 10.1126/science.1465616. [DOI] [PubMed] [Google Scholar]
  28. Mukherji B., Chakraborty N. G., Yamasaki S., Okino T., Yamase H., Sporn J. R., Kurtzman S. K., Ergin M. T., Ozols J., Meehan J. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):8078–8082. doi: 10.1073/pnas.92.17.8078. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Muscatelli F., Walker A. P., De Plaen E., Stafford A. N., Monaco A. P. Isolation and characterization of a MAGE gene family in the Xp21.3 region. Proc Natl Acad Sci U S A. 1995 May 23;92(11):4987–4991. doi: 10.1073/pnas.92.11.4987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Pardoll D. M. Tumour antigens. A new look for the 1990s. Nature. 1994 Jun 2;369(6479):357–357. doi: 10.1038/369357a0. [DOI] [PubMed] [Google Scholar]
  31. Patard J. J., Brasseur F., Gil-Diez S., Radvanyi F., Marchand M., François P., Abi-Aad A., Van Cangh P., Abbou C. C., Chopin D. Expression of MAGE genes in transitional-cell carcinomas of the urinary bladder. Int J Cancer. 1995 Feb 20;64(1):60–64. doi: 10.1002/ijc.2910640112. [DOI] [PubMed] [Google Scholar]
  32. Rahemtulla A., Fung-Leung W. P., Schilham M. W., Kündig T. M., Sambhara S. R., Narendran A., Arabian A., Wakeham A., Paige C. J., Zinkernagel R. M. Normal development and function of CD8+ cells but markedly decreased helper cell activity in mice lacking CD4. Nature. 1991 Sep 12;353(6340):180–184. doi: 10.1038/353180a0. [DOI] [PubMed] [Google Scholar]
  33. Repique C. J., Kettering J. D., Gridley D. S. Immunosuppression derived from human B-lymphoblastoid and melanoma cell lines. Cancer Invest. 1992;10(3):201–208. doi: 10.3109/07357909209032761. [DOI] [PubMed] [Google Scholar]
  34. Rivière I., Brose K., Mulligan R. C. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):6733–6737. doi: 10.1073/pnas.92.15.6733. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Rubin S. C., Finstad C. L., Federici M. G., Scheiner L., Lloyd K. O., Hoskins W. J. Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer. Cancer. 1994 Mar 1;73(5):1456–1459. doi: 10.1002/1097-0142(19940301)73:5<1456::aid-cncr2820730522>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  36. Russo V., Traversari C., Verrecchia A., Mottolese M., Natali P. G., Bordignon C. Expression of the MAGE gene family in primary and metastatic human breast cancer: implications for tumor antigen-specific immunotherapy. Int J Cancer. 1995 Jun 22;64(3):216–221. doi: 10.1002/ijc.2910640313. [DOI] [PubMed] [Google Scholar]
  37. Salgaller M. L., Weber J. S., Koenig S., Yannelli J. R., Rosenberg S. A. Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide. Cancer Immunol Immunother. 1994 Aug;39(2):105–116. doi: 10.1007/BF01525316. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Schultz-Thater E., Juretic A., Dellabona P., Lüscher U., Siegrist W., Harder F., Heberer M., Zuber M., Spagnoli G. C. MAGE-1 gene product is a cytoplasmic protein. Int J Cancer. 1994 Nov 1;59(3):435–439. doi: 10.1002/ijc.2910590324. [DOI] [PubMed] [Google Scholar]
  39. Seder R. A., Paul W. E. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu Rev Immunol. 1994;12:635–673. doi: 10.1146/annurev.iy.12.040194.003223. [DOI] [PubMed] [Google Scholar]
  40. Steinman R. M. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 1991;9:271–296. doi: 10.1146/annurev.iy.09.040191.001415. [DOI] [PubMed] [Google Scholar]
  41. Takahashi K., Shichijo S., Noguchi M., Hirohata M., Itoh K. Identification of MAGE-1 and MAGE-4 proteins in spermatogonia and primary spermatocytes of testis. Cancer Res. 1995 Aug 15;55(16):3478–3482. [PubMed] [Google Scholar]
  42. Tang D. C., DeVit M., Johnston S. A. Genetic immunization is a simple method for eliciting an immune response. Nature. 1992 Mar 12;356(6365):152–154. doi: 10.1038/356152a0. [DOI] [PubMed] [Google Scholar]
  43. Townsend S. E., Allison J. P. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science. 1993 Jan 15;259(5093):368–370. doi: 10.1126/science.7678351. [DOI] [PubMed] [Google Scholar]
  44. Traversari C., van der Bruggen P., Luescher I. F., Lurquin C., Chomez P., Van Pel A., De Plaen E., Amar-Costesec A., Boon T. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med. 1992 Nov 1;176(5):1453–1457. doi: 10.1084/jem.176.5.1453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Ulmer J. B., Donnelly J. J., Parker S. E., Rhodes G. H., Felgner P. L., Dwarki V. J., Gromkowski S. H., Deck R. R., DeWitt C. M., Friedman A. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 1993 Mar 19;259(5102):1745–1749. doi: 10.1126/science.8456302. [DOI] [PubMed] [Google Scholar]
  46. Van den Eynde B., Peeters O., De Backer O., Gaugler B., Lucas S., Boon T. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med. 1995 Sep 1;182(3):689–698. doi: 10.1084/jem.182.3.689. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Wang B., Merva M., Dang K., Ugen K. E., Williams W. V., Weiner D. B. Immunization by direct DNA inoculation induces rejection of tumor cell challenge. Hum Gene Ther. 1995 Apr;6(4):407–418. doi: 10.1089/hum.1995.6.4-407. [DOI] [PubMed] [Google Scholar]
  48. Wu T. C., Huang A. Y., Jaffee E. M., Levitsky H. I., Pardoll D. M. A reassessment of the role of B7-1 expression in tumor rejection. J Exp Med. 1995 Nov 1;182(5):1415–1421. doi: 10.1084/jem.182.5.1415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Xiang Z., Ertl H. C. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity. 1995 Feb;2(2):129–135. doi: 10.1016/s1074-7613(95)80001-8. [DOI] [PubMed] [Google Scholar]
  50. Young M. R., Wright M. A., Coogan M., Young M. E., Bagash J. Tumor-derived cytokines induce bone marrow suppressor cells that mediate immunosuppression through transforming growth factor beta. Cancer Immunol Immunother. 1992;35(1):14–18. doi: 10.1007/BF01741049. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. el-Shirbiny A. M. Prostatic specific antigen. Adv Clin Chem. 1994;31:99–133. doi: 10.1016/s0065-2423(08)60334-0. [DOI] [PubMed] [Google Scholar]
  52. van der Bruggen P., Bastin J., Gajewski T., Coulie P. G., Boël P., De Smet C., Traversari C., Townsend A., Boon T. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol. 1994 Dec;24(12):3038–3043. doi: 10.1002/eji.1830241218. [DOI] [PubMed] [Google Scholar]
  53. van der Bruggen P., Szikora J. P., Boël P., Wildmann C., Somville M., Sensi M., Boon T. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601. Eur J Immunol. 1994 Sep;24(9):2134–2140. doi: 10.1002/eji.1830240930. [DOI] [PubMed] [Google Scholar]
  54. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., Knuth A., Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991 Dec 13;254(5038):1643–1647. doi: 10.1126/science.1840703. [DOI] [PubMed] [Google Scholar]
  55. zur Hausen H., de Villiers E. M. Human papillomaviruses. Annu Rev Microbiol. 1994;48:427–447. doi: 10.1146/annurev.mi.48.100194.002235. [DOI] [PubMed] [Google Scholar]

Articles from Molecular Medicine are provided here courtesy of The Feinstein Institute for Medical Research at North Shore LIJ

RESOURCES